戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 associated Kaposi's sarcoma and multicentric Castleman's disease.
2 si's sarcoma, primary effusion lymphoma, and Castleman's disease.
3 sion lymphoma and some cases of multicentric Castleman's disease.
4 ty-based lymphomas (BCBL), and some forms of Castleman's disease.
5 imary effusion lymphoma, and a proportion of Castleman's disease.
6 or at least 33% of all cases of multicentric Castleman's disease.
7 odgkin's lymphomas (NHL) and in multicentric Castleman's disease.
8 y-based lymphomas (BCBL) and in multicentric Castleman's disease.
9 sed lymphomas, and AIDS-related multicentric Castleman's disease.
10 , and from a high proportion of multicentric Castleman's disease.
11  primary effusion lymphoma, and multicentric Castleman's disease.
12 y effusion B-cell lymphoma, and multicentric Castleman's disease.
13 an's disease from 1923 cases of multicentric Castleman's disease.
14  primary effusion lymphoma, and multicentric Castleman's disease.
15 for, and outcomes of idiopathic multicentric Castleman's disease.
16 uch cases are called idiopathic multicentric Castleman's disease.
17 ry effusion lymphoma (PEL), and multicentric Castleman's disease.
18 ry effusion lymphoma (PEL), and multicentric Castleman's disease.
19  primary effusion lymphoma, and multicentric Castleman's disease.
20 6-in HIV-negative patients with multicentric Castleman's disease.
21 ative patients with symptomatic multicentric Castleman's disease.
22 ry effusion lymphoma (PEL), and multicentric Castleman's disease.
23  primary effusion lymphoma, and multicentric Castleman's disease.
24 g primary effusion lymphoma and multicentric Castleman's disease.
25 ary effusion lymphoma (PEL) and multicentric Castleman's disease.
26  primary effusion lymphoma, and multicentric Castleman's disease.
27 ry effusion lymphoma (PEL), and multicentric Castleman's disease.
28 nd the plasmablastic variant of multicentric Castleman's disease.
29 f primary effusion lymphoma and multicentric Castleman's disease.
30 g primary effusion lymphoma and multicentric Castleman's disease.
31 primary effusion lymphomas, and multicentric Castleman's disease.
32  primary effusion lymphoma, and multicentric Castleman's disease.
33 ion lymphoma, and some forms of multicentric Castleman's disease.
34  primary effusion lymphoma, and multicentric Castleman's disease.
35  primary effusion lymphoma, and multicentric Castleman's disease.
36  primary effusion lymphoma, and multicentric Castleman's disease.
37 ry effusion lymphoma (PEL), and multicentric Castleman's disease.
38 ion lymphoma, and plasmablastic multicentric Castleman's disease.
39  primary effusion lymphoma, and multicentric Castleman's disease.
40  primary effusion lymphoma, and multicentric Castleman's disease.
41 ondylitis, familial Mediterranean fever, and Castleman's disease.
42 f primary effusion lymphoma and multicentric Castleman's disease.
43  primary effusion lymphoma, and multicentric Castleman's disease.
44 a and the plasmablastic form of multicentric Castleman's disease.
45 n lymphoma and in some cases of multicentric Castleman's disease.
46 thritis, hypercalcemia, cancer cachexia, and Castleman's disease.
47  primary effusion lymphoma, and multicentric Castleman's disease.
48 n primary effusion lymphoma and multicentric Castleman's disease.
49 , primary effusion lymphoma and multicentric Castleman's disease.
50  primary effusion lymphoma, and multicentric Castleman's disease.
51 i's sarcoma, body cavity-based lymphoma, and Castleman's disease.
52 ry effusion lymphoma (PEL), and multicentric Castleman's disease.
53  primary effusion lymphoma, and multicentric Castleman's disease.
54  primary effusion lymphoma, and multicentric Castleman's disease.
55 dy cavity-based lymphomas, and some forms of Castleman's disease.
56  primary effusion lymphoma, and multicentric Castleman's disease.
57 V-associated diseases including multicentric Castleman's disease and non-Hodgkin's lymphoma.
58 s, the plasmablastic variant of multicentric Castleman's disease and PEL.
59  lymphoproliferative disorders, multicentric Castleman's disease and primary effusion lymphoma.
60 ma-herpesvirus that causes Kaposi's sarcoma, Castleman's disease and primary effusion lymphomas in tr
61 e for patients with symptomatic multicentric Castleman's disease and well tolerated with prolonged ex
62 from January, 1995, with keywords including "Castleman's disease" and "giant lymph node hyperplasia".
63 ogic agent of Kaposi's sarcoma, multicentric Castleman's disease, and AIDS-associated primary effusio
64 ) are associated with Kaposi's sarcoma (KS), Castleman's disease, and body cavity-based lymphomas (BC
65 ses primary effusion lymphomas, multicentric Castleman's disease, and Kaposi's sarcoma.
66 oma, primary effusion lymphoma, multicentric Castleman's disease, and KSHV inflammatory cytokine synd
67 (KS), the plasmablastic form of multicentric Castleman's disease, and primary effusion lymphoma.
68 tive agent of Kaposi's sarcoma, multicentric Castleman's disease, and primary effusion lymphoma.
69 (KS), the plasmablastic form of multicentric Castleman's disease, and primary effusion lymphoma.
70 V-8) and its etiologic associations with KS, Castleman's disease, and primary effusion lymphomas.
71  etiologic agent for KS tumors, multicentric Castleman's disease, and primary effusion lymphomas.
72 found in Kaposi's sarcoma (KS), multicentric Castleman's disease, and primary effusion lymphomas.
73 rimary effusion lymphoma (PEL), multicentric Castleman's disease, and two inflammatory diseases.
74 si's sarcoma, primary effusion lymphoma, and Castleman's disease are the major malignancies associate
75 lopment of Kaposi's sarcoma and multicentric Castleman's disease, as well as a rare form of B cell ly
76 h primary effusion lymphoma and multicentric Castleman's disease, as well as its namesake Kaposi's sa
77 plasia to monoclonal neoplasia: multicentric Castleman's disease (CD), Kaposi's sarcoma (KS), and pri
78 of the atypical lymphoproliferative disorder Castleman's disease (CD).
79 y effusion lymphomas (PELs), and a subset of Castleman's disease (CD).
80 ling the multicentric plasma cell variant of Castleman's disease, characterized by persistent angiofo
81                          We report a case of Castleman's disease demonstrating 18F-fluorodeoxyglucose
82                                 Multicentric Castleman's disease describes a group of poorly understo
83 si's sarcoma, primary effusion lymphoma, and Castleman's disease, encodes several pathogenically impo
84 3%) patients with HHV8-negative multicentric Castleman's disease from 1923 cases of multicentric Cast
85 e as an imaging modality for differentiating Castleman's disease from lymphoma.
86 of 128 patients with idiopathic multicentric Castleman's disease had a diagnosis of a separate malign
87 man herpesvirus 8 (HHV8) causes multicentric Castleman's disease in immunosuppressed patients.
88  Inclusion criteria were pathology-confirmed Castleman's disease in multiple nodes and minimum clinic
89  primary effusion lymphoma, and multicentric Castleman's disease; in all of these diseases, interleuk
90 -line treatments for idiopathic multicentric Castleman's disease included corticosteroids (47/128 [37
91 Clinical features of idiopathic multicentric Castleman's disease included multicentric lymphadenopath
92                                 Multicentric Castleman's disease is a rare lymphoproliferative disord
93                                              Castleman's disease is a rare primary disease of the lym
94      The cause of HHV8-negative multicentric Castleman's disease is idiopathic; such cases are called
95 irus (HIV)-associated lymphadenopathy with a Castleman's disease-like appearance.
96 ted in KSHV-positive cells from multicentric Castleman's disease (MCD) and Kaposi's sarcoma (KS) lesi
97 on lymphoma (PEL) and a form of multicentric Castleman's disease (MCD) are both caused by Kaposi sarc
98                                 Multicentric Castleman's disease (MCD) describes a heterogeneous grou
99 phoma (PEL) cell lines, PEL and multicentric Castleman's disease (MCD) tumors, Kaposi's sarcoma lesio
100 ry effusion lymphoma (PEL), and multicentric Castleman's disease (MCD), all of which are viewed as cy
101 inked to Kaposi's sarcoma (KS), multicentric Castleman's disease (MCD), and primary effusion lymphoma
102 ncluding Kaposi's sarcoma (KS), multicentric Castleman's disease (MCD), and primary effusion lymphoma
103 rimary effusion lymphoma (PEL), multicentric Castleman's disease (MCD), and the inflammation-driven n
104 ry effusion lymphoma (PEL), and multicentric Castleman's disease (MCD), in addition to an MCD-related
105 iated Kaposi's sarcoma, PEL and multicentric Castleman's disease (MCD), in addition to proinflammator
106  (UCD) or the dominant focus in multicentric Castleman's disease (MCD), nature of the surgical approa
107 ry effusion lymphoma (PEL), and multicentric Castleman's disease (MCD), three diseases that frequentl
108 ymphomas (PEL), and a subset of multicentric Castleman's disease (MCD).
109 primary effusion lymphomas, and multicentric Castleman's disease (MCD).
110 homas (BCBLs) and in lesions of multicentric Castleman's disease (MCD).
111 ry effusion lymphoma (PEL), and multicentric Castleman's disease (MCD).
112 ry effusion lymphoma (PEL), and multicentric Castleman's disease (MCD).
113 ry effusion lymphoma (PEL), and multicentric Castleman's disease (MCD).
114 ry effusion lymphoma (PEL), and multicentric Castleman's disease (MCD).
115 ary effusion lymphoma (PEL) and multicentric Castleman's disease (MCD).
116  primary effusion lymphoma, and multicentric Castleman's disease (MCD).
117 ry effusion lymphoma (PEL), and multicentric Castleman's disease (MCD).
118 ry effusion lymphomas (PEL) and multicentric Castleman's disease (MCD).
119    128 patients with idiopathic multicentric Castleman's disease met all inclusion criteria for the s
120 tic pemphigus (including 10 with concomitant Castleman's disease) nor from 19 patients with pemphigus
121 nt of three human malignancies: multicentric Castleman's disease, primary effusion lymphoma, and Kapo
122 ed information about idiopathic multicentric Castleman's disease represents a major challenge for cli
123 ted with human herpesvirus-8 in multicentric Castleman's disease support lytic replication, so that c
124 ated with both malignancies and multicentric Castleman's disease; the latter is a rare angiolymphopro
125  less commonly primary effusion lymphoma and Castleman's disease; these neoplastic diseases are repor
126 ry effusion lymphoma (PEL), and multicentric Castleman's disease through autocrine or paracrine mecha
127      K1 was readily detected in multicentric Castleman's disease tissues, whereas it was not detected
128  systematic review of 404 published cases of Castleman's disease to identify the role of the surgeon
129 cal location of the only focus in unicentric Castleman's disease (UCD) or the dominant focus in multi
130 or 127 patients with idiopathic multicentric Castleman's disease were presented from clinical trials,
131 ent, and outcomes of idiopathic multicentric Castleman's disease, which accounts for at least 33% of
132 there is mild FDG localization within pelvic Castleman's disease with standard uptake values lower th

 
Page Top